Literature DB >> 12007217

The IARC TP53 database: new online mutation analysis and recommendations to users.

Magali Olivier1, Ros Eeles, Monica Hollstein, Mohammed A Khan, Curtis C Harris, Pierre Hainaut.   

Abstract

Mutations in the tumor suppressor gene TP53 are frequent in most human cancers. Comparison of the mutation patterns in different cancers may reveal clues on the natural history of the disease. Over the past 10 years, several databases of TP53 mutations have been developed. The most extensive of these databases is maintained and developed at the International Agency for Research on Cancer. The database compiles all mutations (somatic and inherited), as well as polymorphisms, that have been reported in the published literature since 1989. The IARC TP53 mutation dataset is the largest dataset available on the variations of any human gene. The database is available at www.iarc.fr/P53/. In this paper, we describe recent developments of the database. These developments include restructuring of the database, which is now patient-centered, with more detailed annotations on the patient (carcinogen exposure, virus infection, genetic background). In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12007217     DOI: 10.1002/humu.10081

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  380 in total

1.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Authors:  Mandy L Ballinger; Ana Best; Phuong L Mai; Payal P Khincha; Jennifer T Loud; June A Peters; Maria Isabel Achatz; Rubens Chojniak; Alexandre Balieiro da Costa; Karina Miranda Santiago; Judy Garber; Allison F O'Neill; Rosalind A Eeles; D Gareth Evans; Eveline Bleiker; Gabe S Sonke; Marielle Ruijs; Claudette Loo; Joshua Schiffman; Anne Naumer; Wendy Kohlmann; Louise C Strong; Jasmina Bojadzieva; David Malkin; Surya P Rednam; Elena M Stoffel; Erika Koeppe; Jeffrey N Weitzel; Thomas P Slavin; Bita Nehoray; Mark Robson; Michael Walsh; Lorenzo Manelli; Anita Villani; David M Thomas; Sharon A Savage
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

2.  Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Authors:  Bojan Jelaković; Sandra Karanović; Ivana Vuković-Lela; Frederick Miller; Karen L Edwards; Jovan Nikolić; Karla Tomić; Neda Slade; Branko Brdar; Robert J Turesky; Želimir Stipančić; Damir Dittrich; Arthur P Grollman; Kathleen G Dickman
Journal:  Kidney Int       Date:  2011-11-09       Impact factor: 10.612

3.  Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Kaustubh Bhinge; Vineet Gupta; Xin Gu; S Michal Jazwinski
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

4.  Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers.

Authors:  Ivan P Gorlov; Olga Y Gorlova; Marsha L Frazier; Christopher I Amos
Journal:  Am J Hum Genet       Date:  2003-10-01       Impact factor: 11.025

5.  Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.

Authors:  Michael A Resnick; Alberto Inga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

6.  The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.

Authors:  David Dornan; Harumi Shimizu; Lindsay Burch; Amanda J Smith; Ted R Hupp
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

7.  Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.

Authors:  Taeyoung Koo; Il-Kyu Choi; Minjung Kim; Jung-Sun Lee; Eonju Oh; Jungho Kim; Chae-Ok Yun
Journal:  Hum Gene Ther       Date:  2012-02-21       Impact factor: 5.695

8.  The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein.

Authors:  Michela Muscolini; Elisa Montagni; Vanessa Palermo; Silvia Di Agostino; Wei Gu; Salma Abdelmoula-Souissi; Cristina Mazzoni; Giovanni Blandino; Loretta Tuosto
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

9.  Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR.

Authors:  Jin Li; Lilin Wang; Pasi A Jänne; G Mike Makrigiorgos
Journal:  Clin Chem       Date:  2009-02-20       Impact factor: 8.327

10.  Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.

Authors:  Dania Al Labban; Seung-Hee Jo; Paola Ostano; Chiara Saglietti; Massimo Bongiovanni; Renato Panizzon; G Paolo Dotto
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.